Loading clinical trials...
Loading clinical trials...
A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese Adults
Conditions
Interventions
AZD7442 IM
Placebo IM
+6 more
Locations
2
China
Research Site
Guangzhou, China
Research Site
Shanghai, China
Start Date
October 9, 2021
Primary Completion Date
November 27, 2021
Completion Date
January 16, 2023
Last Updated
March 31, 2023
NCT00104325
NCT07118891
NCT03878121
NCT01399385
NCT07295717
NCT03807401
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions